Clinical Outcomes and Serum B-Cell Maturation Antigen Levels in a Real-World Unselected Population of Newly Diagnosed Multiple Myeloma Patients
Reference: James R. Berenson, MD Berenson Cancer Center
Article
Ruxolitinib Is Under Investigation as JAK Inhibition Strategy for Multiple Myeloma
CancerNetwork® spoke with James R. Berenson, MD, founder, medical and scientific director, and president and chief...